The Microbiome Business & Science Briefing
MicrobimeTimes
Reporting on The Latest Microbiome Business & Scientific Developments
TRENDING
The Oral Delivery Challenge: Why It Requires More Than the Right Route• Microbial systems are a black box. We created Microbial INtelligence Explorer to “MINE” their secrets• Microbiotica Raises $48 Million Series C to Advance Pipeline into Phase 2 Clinical Development• Prokarium: Leading the Evolution of Bacterial Immunotherapy, the Next Frontier in Cancer Treatment• Claude Discovers Novel Enzyme System with CRISPR-like Repeats• New Clinical Study Aims to Find Out if FMT capsules could help better manage anorexia•

Category: Gastrointestinal

Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test
Gastrointestinal

Prescient Metabiomics and CoreBiome collaborating to develop breakthrough colon cancer screening test

DEC 17, 2019
Beware probiotics in ICU patients
Biotics and Supplements

Beware probiotics in ICU patients

NOV 20, 2019
Fecal transplantation to treat patients with Parkinson’s disease: Hope or hype?
Biotics and Supplements

Fecal transplantation to treat patients with Parkinson’s disease: Hope or hype?

NOV 19, 2019
Half of all commonly used drugs profoundly affecting the gut microbiome, warn experts
Gastrointestinal

Half of all commonly used drugs profoundly affecting the gut microbiome, warn experts

OCT 26, 2019
Gut bacteria ‘fingerprint’ predicts radiotherapy side effects
Gastrointestinal

Gut bacteria ‘fingerprint’ predicts radiotherapy side effects

OCT 9, 2019
Biomica Advances to Pre-Clinical Studies in its IBD Program
Gastrointestinal

Biomica Advances to Pre-Clinical Studies in its IBD Program

OCT 4, 2019
Precision editing of gut bacteria reduces cancer in mice
Gastrointestinal

Precision editing of gut bacteria reduces cancer in mice

AUG 7, 2019
3D printed pill samples gut microbiome to aid diagnosis and treatment
Gastrointestinal

3D printed pill samples gut microbiome to aid diagnosis and treatment

JUL 25, 2019
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
Clinical & Manufacturing

Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance

JUL 6, 2019
Webinar: Improving Ulcerative Colitis Symptoms with Probiotics
Biotics and Supplements

Webinar: Improving Ulcerative Colitis Symptoms with Probiotics

JUN 12, 2019
Five-minute Microbiome Science Roundup: May 2019
Editor's Choice

Five-minute Microbiome Science Roundup: May 2019

JUN 5, 2019